Finanznachrichten4d
DelveInsight Business Research, LLP: 75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight
In September 2024, Sanofi announced the outcomes of Phase III clinical trials of its investigational oral brain-penetrant BTK inhibitor, tolebrutinib, aimed at treating multiple sclerosis (MS). These ...
Sanofi’s Dupixent Gains EU Approval for Pediatric Eosinophilic Esophagitis
Sanofi (SNY) has released an update. Sanofi’s Dupixent has received EU approval as the first treatment for children aged one to 11 with ...
Regeneron, Sanofi announce EC approval for Dupixent
Regeneron (REGN) and Sanofi (SNY) announced that the European Commission, or EC, has approved Dupixent to treat eosinophilic esophagitis, or ...
labiotech13d
From consumer health to pure biopharma: Inside Sanofi’s strategic shift
Delve into Sanofi's "play to win" strategy as investments are ramping up after their consumer health division's divestment.
Nasdaq20d
Sanofi Launches Beyfortus Immunization Against RSV For Infants In Canada This Fall
(RTTNews) - Sanofi announced that Beyfortus (nirsevimab) will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon this fall. The administration ...
FiercePharma24d
Sanofi shrugs off potential RSV competition from Merck as Beyfortus grows sales 382%
Despite Merck & Co. homing in on approval for its infant respiratory syncytial virus (RSV) antibody clesrovimab, Sanofi—which last year won its own nod for its AstraZeneca-partnered RSV ...
Sanofi Earnings Get Boost From Early Vaccine Sales
The pharmaceutical company reported third-quarter earnings and sales that beat analysts’ expectations, boosted by ...
Benzinga.com24d
Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine Sales, Raises 2024 Forecast
Sanofi expects a low single-digit decline in flu shot sales due to the soft vaccination rate. Sanofi reaffirms that Dupixent will deliver around 13 billion euros in 2024 sales. The company ...
BioSpace24d
Sanofi Beats Q3 Forecasts Fueled by 381% Growth in Beyfortus Sales
Leerink Partners analyst David Risinger in a Friday note to investors said Sanofi expects Q4 Beyfortus sales similar to Q3. Sanofi released its third-quarter earnings report on Friday, beating ...
PR Newswire25d
Appian Appoints Americo Mazzotta as Vice President of EMEA Sales
Notable customers include Santander in financial services, Sanofi in life sciences, Serco in the public sector, Poste Italiane in transportation, and more. Under his leadership, Appian ...
Law27d
A Legion of Law Firms Advise on Sanofi's Potential Sale of Consumer Health Care Unit to US Private Equity Fund
France's biggest-selling medication. Freshfields is advising Sanofi on corporate and consumer healthcare aspects of the deal, which is valued at around €16 billion ($17.28 billion). Sanofi would ...
Politico27d
FTC’s merger play
jobs and management in France after the American takeover. Under the deal signed by Sanofi, CD&R and the government, Opella must pay a €40 million ($43.3 million) penalty if it stops production ...